Anorexia-cachexia syndrome in cancer: Implications of the ubiquitin-proteasome pathway

Supportive Care in Cancer

Volumn 14, Issue 12, 2006, Pages 1173-1183

  Camps, Carlos ^a   Iranzo, Vega ^a   Bremnes, Roy M ^b,c   Sirera, Rafael ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Anorexia; Cachexia; Cancer; Proteasome; Ubiquitin

Indexed keywords

APPETITE STIMULANT; CANCER GROWTH FACTOR; CANNABINOID; CILIARY NEUROTROPHIC FACTOR; CORTICOTROPIN RELEASING FACTOR; CYPROHEPTADINE; CYTOKINE; GESTAGEN; GLUCAGON; GLUCOCORTICOID; GLYCOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MITOGEN ACTIVATED PROTEIN KINASE 1; NEUROPEPTIDE Y; PROTEASOME; PROTEASOME INHIBITOR; PROTEOLYSIS INDUCTION FACTOR; SEROTONIN; SEROTONIN ANTAGONIST; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANOREXIA; APOPTOSIS; CACHEXIA; CANCER; CANCER MORTALITY; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; IMMUNE RESPONSE; INCIDENCE; MALNUTRITION; MORBIDITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; WEIGHT REDUCTION;

ANOREXIA; CACHEXIA; HUMANS; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOGLYCANS; SIGNAL TRANSDUCTION; SYNDROME; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN;

EID: 33751304874     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-006-0097-7     Document Type: Review

References (137)

1. Barber MD, Ross JA, Fearon KC (1999) Cancer cachexia. Surg Oncol 8:133-141
2. Bruera E (1997) ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ 315:1219-1222
3. Kotler DP (2000) Cachexia. Ann Intern Med 133:622-634
4. Larkin M (1998) Thwarting the dwindling progression of cachexia. Lancet 351:1336
5. Tisdale MJ (1997) Biology of cachexia. J Natl Cancer Inst 89:1763-1773
6. Dewys WD, Begg C, Lavin PT et al (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69:491-497
7. Puccio M, Nathanson L (1997) The cancer cachexia syndrome. Semin Oncol 24:277-287
8. Garattini S, Bizzi A, Donelli MG et al (1980) Anorexia and cancer in animals and man. Cancer Treat Rev 7:115-139
9. Ovesen L, Allingstrup L, Hannibal J et al (1993) Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol 11:2043-2049
10. Inui A (2002) Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 52:72-91
11. Tisdale MJ (2003) Pathogenesis of cancer cachexia. J Support Oncol 1:159-168
12. Van Cutsem E, Arends J (2005) The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs 9(Suppl 2):S51-S63
13. Todorov P, Cariuk P, McDevitt T et al (1996) Characterization of a cancer cachectic factor. Nature 379:739-742
14. Watchorn TM, Dowidar N, Dejong CH et al (2005) The cachectic mediator proteolysis inducing factor activates NF-kappaB and STAT3 in human Kupffer cells and monocytes. Int J Oncol 27:1105-1111
15. Tisdale MJ (2000) Metabolic abnormalities in cachexia and anorexia. Nutrition 16:1013-1014
16. Tisdale MJ (2001) Cancer anorexia and cachexia. Nutrition 17:438-442
17. Tisdale MJ (2004) Tumor-host interactions. J Cell Biochem 93:871-877
18. Tayek JA (1992) A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am Coll Nutr 11:445-456
19. Lecker SH, Solomon V, Mitch WE et al (1999) Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr 129(1S Suppl):227S-237S
20. Wyke SM, Russell ST, Tisdale MJ (2004) Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation. Br J Cancer 91:1742-1750
21. Wyke SM, Tisdale MJ (2005) NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle. Br J Cancer 92:711-721
22. Tisdale MJ (2005) The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting. J Support Oncol 3:209-217
23. Argiles JM, Lopez-Soriano FJ (1996) The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. Trends Pharmacol Sci 17:223-226
24. Garcia-Martinez C, Costelli P, Lopez-Soriano FJ et al (1997) Is TNF really involved in cachexia? Cancer Invest 15:47-54
25. Acharyya S, Ladner KJ, Nelsen LL et al (2004) Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 114:370-378
26. Baldwin C, Parsons T, Logan S (2001) Dietary advice for illness-related malnutrition in adults. Cochrane Database Syst Rev CD002008
27. Alexandre J, Gross-Goupil M, Falissard B et al (2003) Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. Ann Oncol 14:36-41
28. Walsh D, Rybicki L, Nelson KA et al (2002) Symptoms and prognosis in advanced cancer. Support Care Cancer 10:385-388
29. Ottery FD (1994) Cancer cachexia: prevention, early diagnosis, and management. Cancer Pract 2:123-131
30. Capra S, Ferguson M, Ried K (2001) Cancer: impact of nutrition intervention outcome-nutrition issues for patients. Nutrition 17:769-772
31. Harvie MN, Campbell IT, Thatcher N et al (2003) Changes in body composition in men and women with advanced nonsmall cell lung cancer (NSCLC) undergoing chemotherapy. J Hum Nutr Diet 16:323-326
32. Berteretche MV, Dalix AM, d'Ornano AM et al (2004) Decreased taste sensitivity in cancer patients under chemotherapy. Support Care Cancer 12:571-576
33. Nelson KA, Walsh D, Sheehan FA (1994) The cancer anorexia-cachexia syndrome. J Clin Oncol 12:213-225
34. Segura (2005) Segura A, Jara C, Pardo J et al (2003) Epidemiological evaluation of nutritional status (NS) in patients (P) with locally-advanced or metastatic cancer (LAMC) ("NUPAC"). Proc Am Soc Clin Oncol 22:776 (Abstract 3120)
35. Fearon KC, Barber MD, Falconer JS et al (1999) Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J Surg 23:584-588
36. Inui A (1999) Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res 59:4493-4501
37. Davis MP, Dickerson D (2000) Cachexia and anorexia: cancer's covert killer. Support Care Cancer 8:180-187
38. Woods SC, Seeley RJ, Porte D Jr et al (1998) Signals that regulate food intake and energy homeostasis. Science 280:1378-1383
39. Argiles JM, Busquets S, Garcia-Martinez C et al (2005) Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future. Nutrition 21:977-985
40. Illman J, Corringham R, Robinson D Jr et al (2005) Are inflammatory cytokines the common link between cancer-associated cachexia and depression? J Support Oncol 3:37-50
41. Todorov PT, Field WN, Tisdale MJ (1999) Role of a proteolysis-inducing factor (PIF) in cachexia induced by a human melanoma (G361). Br J Cancer 80:1734-1737
42. Rubin H (2003) Cancer cachexia: its correlations and causes. Proc Natl Acad Sci USA 100:5384-5389
43. Krause R, James JH, Ziparo V et al (1979) Brain tryptophan and the neoplastic anorexia-cachexia syndrome. Cancer 44:1003-1008
44. Gorwood P (2004) Eating disorders, serotonin transporter polymorphisms and potential treatment response. Am J Pharmacogenomics 4:9-17
45. Jensen PB, Blume N, Mikkelsen JD et al (1998) Transplantable rat glucagonomas cause acute onset of severe anorexia and adipsia despite highly elevated NPY mRNA levels in the hypothalamic arcuate nucleus. J Clin Invest 101:503-510
46. Chance WT, Balasubramaniam A, Thompson H et al (1996) Assessment of feeding response of tumor-bearing rats to hypothalamic injection and infusion of neuropeptide Y. Peptides 17:797-801
47. Myung CS, Kim BT, Choi SH et al (2005) Role of neuropeptide Y and proopiomelanocortin in fluoxetine-induced anorexia. Arch Pharm Res 28:716-721
48. McCarthy DO, Daun JM (1993) The effects of cyclooxygenase inhibitors on tumor-induced anorexia in rats. Cancer 71:486-492
49. Friedman JM (1998) Leptin, leptin receptors, and the control of body weight. Nutr Rev 56:s38-s46
50. Bosaeus I, Daneryd P, Svanberg E et al (2001) Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. Int J Cancer 93:380-383
51. Harvie MN, Campbell IT (2000) Energy balance, cancer and the sympathetic nervous system. Eur J Cancer 36:289-292
52. Young VR (1977) Energy metabolism and requirements in the cancer patient. Cancer Res 37:2336-2347
53. Hirai K, Hussey HJ, Barber MD et al (1998) Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res 58:2359-2365
54. Rock KL, Goldberg AL (1999) Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 17:739-779
55. Goll DE, Thompson VF, Taylor RG et al (1992) Role of the calpain system in muscle growth. Biochimie 74:225-237
56. Coux O, Tanaka K, Goldberg AL (1996) Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 65:801-847
57. Adams J (2003) The proteasome: structure, function, and role in the cell. Cancer Treat Rev 29(Suppl 1):3-9
58. Kisselev AF, Goldberg AL (2001) Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8:739-758
59. Zwickl P, Voges D, Baumeister W (1999) The proteasome: a macromolecular assembly designed for controlled proteolysis. Philos Trans R Soc Lond B Biol Sci 354:1501-1511
60. Gerards WL, de Jong WW, Boelens W et al (1998) Structure and assembly of the 20S proteasome. Cell Mol Life Sci 54:253-262
61. Groll M, Koguchi Y, Huber R et al (2001) Crystal structure of the 20 S proteasome: TMC-95A complex: a non-covalent proteasome inhibitor. J Mol Biol 311:543-548
62. Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82:373-428
63. Goldberg AL, Akopian TN, Kisselev AF et al (1997) New insights into the mechanisms and importance of the proteasome in intracellular protein degradation. Biol Chem 378:131-140
64. DeMartino GN, Slaughter CA (1999) The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem 274:22123-22126
65. Hershko A, Heller H, Elias S et al (1983) Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J Biol Chem 258:8206-8214
66. Wing SS, Haas AL, Goldberg AL (1995) Increase in ubiquitin-protein conjugates concomitant with the increase in proteolysis in rat skeletal muscle during starvation and atrophy denervation. Biochem J 307(Pt 3):639-645
67. Medina R, Wing SS, Goldberg AL (1995) Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle during starvation and denervation atrophy. Biochem J 307(Pt 3):631-637
68. Williams A, Sun X, Fischer JE et al (1999) The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery 126:744-749
69. Smith KL, Tisdale MJ (1993) Increased protein degradation and decreased protein synthesis in skeletal muscle during cancer cachexia. Br J Cancer 67:680-685
70. Bossola M, Muscaritoli M, Costelli P et al (2001) Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol Regul Integr Comp Physiol 280:R1518-R1523
71. Ling YH, Liebes L, Ng B et al (2002) PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 1:841-849
72. Orlowski RZ, Baldwin AS Jr (2002) NF-kappaB as a therapeutic target in cancer. Trends Mol Med 8:385-389
73. Kuroda K, Horiguchi Y, Nakashima J et al (2005) Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer. Clin Cancer Res 11:5590-5594
74. Ni H, Ergin M, Huang Q et al (2001) Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol 115:279-286
75. Cross TG, Scheel-Toellner D, Henriquez NVet al (2000) Serine/threonine protein kinases and apoptosis. Exp Cell Res 256:34-41
76. Schaeffer HJ, Weber MJ (1999) Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 19:2435-2444
77. Dent P, Jarvis WD, Birrer MJ et al (1998) The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity. Leukemia 12:1843-1850
78. Ryden M, Arvidsson E, Blomqvist L et al (2004) Targets for TNF-alpha-induced lipolysis in human adipocytes. Biochem Biophys Res Commun 318:168-175
79. Smith HJ, Tisdale MJ (2003) Signal transduction pathways involved in proteolysis-inducing factor induced proteasome expression in murine myotubes. Br J Cancer 89:1783-1788
80. Santen RJ, Song RX, McPherson R et al (2002) The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 80:239-256
81. Lee JT Jr, McCubrey JA (2002) The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia 16:486-507
82. Kudo Y, Takata T, Ogawa I et al (2000) p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin Cancer Res 6:916-923
83. Wagenknecht B, Hermisson M, Eitel K et al (1999) Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells. Cell Physiol Biochem 9:117-125
84. de Lima TM, Lima MM, Almeida DC et al (2005) Cachexia induced by Walker 256 tumor growth causes rat lymphocyte death. Cancer Immunol Immunother 54:179-186
85. Smith HJ, Tisdale MJ (2003) Induction of apoptosis by a cachectic-factor in murine myotubes and inhibition by eicosapentaenoic acid. Apoptosis 8:161-169
86. Cabal-Manzano R, Bhargava P, Torres-Duarte A et al (2001) Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br J Cancer 84:1599-1601
87. Teich N, Kleeff J, Lochs H et al (2005) The presence of the proteolysis-inducing factor in urine does not predict the malignancy of a pancreatic tumour. BMC Gastroenterol 5:20
88. Deans DA, Wigmore SJ, Gilmour H et al (2006) Expression of the proteolysis-inducing factor core peptide mRNA is upregulated in both tumour and adjacent normal tissue in gastro-oesophageal malignancy. Br J Cancer 94:731-736
89. Smith HJ, Lorite MJ, Tisdale MJ (1999) Effect of a cancer cachectic factor on protein synthesis/degradation in murine C2C12 myoblasts: modulation by eicosapentaenoic acid. Cancer Res 59:5507-5513
90. Whitehouse AS, Tisdale MJ (2001) Downregulation of ubiquitin-dependent proteolysis by eicosapentaenoic acid in acute starvation. Biochem Biophys Res Commun 285:598-602
91. Watchorn TM, Waddell I, Ross JA (2002) Proteolysis-inducing factor differentially influences transcriptional regulation in endothelial subtypes. Am J Physiol Endocrinol Metab 282:E763-E769
92. Beutler BA, Milsark IW, Cerami A (1985) Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol 135:3972-3977
93. Garcia-Martinez C, Costelli P, Lopez-Soriano FJ et al (1997) Is TNF really involved in cachexia? Cancer Invest 15:47-54
94. Souza SC, Palmer HJ, Kang YH et al (2003) TNF-alpha induction of lipolysis is mediated through activation of the extracellular signal related kinase pathway in 3T3-L1 adipocytes. J Cell Biochem 89:1077-1086
95. Tisdale MJ (1999) Wasting in cancer. J Nutr 129:243S-246S
96. Figueras M, Busquets S, Carbo N et al (2005) Cancer cachexia results in an increase in TNF-alpha receptor gene expression in both skeletal muscle and adipose tissue. Int J Oncol 27:855-860
97. Costelli P, Carbo N, Tessitore L et al (1993) Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest 92:2783-2789
98. Elia M, Van Bokhorst-de van der Schueren MA, Garvey J et al (2006) Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: a systematic review. Int J Oncol 28:5-23
99. Bauer JD, Capra S (2005) Nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapy - a pilot study. Support Care Cancer 13:270-274
100. Odelli C, Burgess D, Bateman L et al (2005) Nutrition support improves patient outcomes, treatment tolerance and admission characteristics in oesophageal cancer. Clin Oncol (R Coll Radiol) 17:639-645
101. Rathmacher JA, Nissen S, Panton L et al (2004) Supplementation with a combination of beta-hydroxy-beta-methylbutyrate (HMB), arginine, and glutamine is safe and could improve hematological parameters. JPEN J Parenter Enteral Nutr 28:65-75
102. Lundholm K, Daneryd P, Bosaeus I et al (2004) Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism, and function. Cancer 100:1967-1977
103. Mantovani G, Maccio A, Massa E et al (2001) Managing cancer-related anorexia/cachexia. Drugs 61:499-514
104. Argiles JM, Meijsing SH, Pallares-Trujillo J et al (2001) Cancer cachexia: a therapeutic approach. Med Res Rev 21:83-101
105. Ramos EJ, Suzuki S, Marks D et al (2004) Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care 7:427-434
106. Nelson KA (2000) The cancer anorexia-cachexia syndrome. Semin Oncol 27:64-68
107. Maltoni M, Nanni O, Scarpi E et al (2001) High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. Ann Oncol 12:289-300
108. Cerchietti LC, Navigante AH, Peluffo GD et al (2004) Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study. J Pain Symptom Manage 27:85-95
109. Martin BR, Wiley JL (2004) Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. J Support Oncol 2:305-314
110. Mattox TW (2005) Treatment of unintentional weight loss in patients with cancer. Nutr Clin Pract 20:400-410
111. Smith HJ, Greenberg NA, Tisdale MJ (2004) Effect of eicosapentaenoic acid, protein and amino acids on protein synthesis and degradation in skeletal muscle of cachectic mice. Br J Cancer 91:408-412
112. Persson C, Glimelius B, Ronnelid J et al (2005) Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomized pilot study. Nutrition 21:170-178
113. Barber MD, Ross JA, Voss AC et al (1999) The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 81:80-86
114. Shirota T, Haji S, Yamasaki M et al (2005) Apoptosis in human pancreatic cancer cells induced by eicosapentaenoic acid. Nutrition 21:1010-1017
115. Bruera E, Strasser F, Palmer JL et al (2003) Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol 21:129-134
116. Russell ST, Tisdale MJ (2005) Effect of eicosapentaenoic acid (EPA) on expression of a lipid mobilizing factor in adipose tissue in cancer cachexia. Prostaglandins Leukot Essent Fatty Acids 72:409-414
117. Fearon KC, Von Meyenfeldt MF, Moses AG et al (2003) Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 52:1479-1486
118. Fanelli M, Sarmiento R, Gattuso D et al (2003) Thalidomide: a new anticancer drug? Expert Opin Investig Drugs 12:1211-1225
119. Gordon JN, Trebble TM, Ellis RD et al (2005) Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54:540-545
120. Khan ZH, Simpson EJ, Cole AT et al (2003) Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment Pharmacol Ther 17:677-682
121. Voorhees PM, Dees EC, O'Neil B et al (2003) The proteasome as a target for cancer therapy. Clin Cancer Res 9:6316-6325
122. Cusack JC (2003) Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 29(Suppl 1):21-31
123. Burger AM, Seth AK (2004) The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer 40:2217-2229
124. Shirley RB, Kaddour-Djebbar I, Patel DM et al (2005) Combination of proteasomal inhibitors lactacystin and MG132 induced synergistic apoptosis in prostate cancer cells. Neoplasia 7:1104-1111
125. Kozlowski L, Stoklosa T, Omura S et al (2001) Lactacystin inhibits cathepsin A activity in melanoma cell lines. Tumour Biol 22:211-215
126. Groll M, Huber R (2004) Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. Biochim Biophys Acta 1695:33-44
127. Bo KK, Fonseca FN, Crews CM (2005) Development and characterization of proteasome inhibitors. Methods Enzymol 399:585-609
128. Meng L, Mohan R, Kwok BH et al (1999) Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 96:10403-10408
129. Meng L, Kwok BH, Sin N et al (1999) Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res 59:2798-2801
130. Kumar B, Hanson AJ, Prasad KN (2004) Sensitivity of proteasome to its inhibitors increases during cAMP-induced differentiation of neuroblastoma cells in culture and causes decreased viability. Cancer Lett 204:53-59
131. Grimes KR, Daosukho C, Zhao Y et al (2005) Proteasome inhibition improves fractionated radiation treatment against non-small cell lung cancer: an antioxidant connection. Int J Oncol 27:1047-1052
132. Adams J, Palombella VJ, Sausville EA et al (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615-2622
133. Mitchell BS (2003) The proteasome - an emerging therapeutic target in cancer. N Engl J Med 348:2597-2598
134. Berenson JR, Yang HH, Sadler K et al (2006) Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 24:937-944
135. Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498
136. Younes A, Pro B, Fayad L (2006) Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood 107:1731-1732
137. Jatoi A, Alberts SR, Foster N et al (2005) Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group. Support Care Cancer 13:381-386